Andrx settles Glucotrol infringement suit
Andrx agrees with Pfizer and Alza to settle patent infringement litigation over the company's ANDA for a generic version of Glucotrol XL (glipizide extended release). All claims were dropped with Andrx agreeing to receive a royalty-bearing sublicense under relevant Alza patents. Andrx believes it was first to file a glipizide ANDA. Andrx filed a citizen's petition with FDA related to the case in November (1"The Pink Sheet" Nov. 11, 2002, p. 25)...
You may also be interested in...
FDA should deem a patent on Pfizer's Glucotrol XL "late-listed," even if it is reissued and listed in the "Orange Book," Andrx says in a 1citizen petition
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.